Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Xtant Medical Holdings, Inc. (XTNT)
USD0.45
-0.01 (-1.90%)
US AMEX Healthcare Medical - Devices
Address
664 Cruiser Lane 59714
Belgrade, MT, US
Belgrade, MT, US
CEO
Sean E. Browne
Website
xtantmedical.com
IPO
2010-07-01
CIK 1453593 ISIN US98420P3082
Description
Xtant Medical Holdings, Inc., a company based in Belgrade, Montana, specializes in the development, production, and distribution of advanced regenerative medicine products and medical devices. The firm primarily serves orthopedic and neurological surgeons both within the United States and globally. Its comprehensive product portfolio is categorized into several key areas: 1. Biomaterial Offerings: This category includes products like OsteoSponge, which provides a natural structural support for cellular growth and introduces vital bone-forming proteins to aid the healing process. OsteoSponge SC is specifically designed to repair bone defects in the subchondral area of joints. Other items are OsteoSelect DBM Putty, fostering osteoinductive bone regeneration, and OsteoSelect PLUS DBM Putty, which functions as a bone void filler and graft substitute for procedures involving the pelvis, extremities, and posterolateral spine. Additionally, the line features OsteoFactor, containing diverse proteins and peptides that facilitate bone formation and remodeling, along with OsteoWrap and OsteoVive Plus, a cellular bone matrix enriched with growth factors. 2. Allograft Technologies: Under the 3Demin brand, Xtant Medical provides a range of allografts (human bone grafts) engineered to maximize both osteoconductivity and osteoinductive capabilities. This includes specialized sports allografts used for repairing anterior and posterior cruciate ligaments, ACL reconstruction, and meniscal repairs. They also offer milled spinal allografts, where cortical bone is precisely shaped to specific dimensions, as well as traditional allografts applicable across numerous medical disciplines such such as orthopedics, neurology, podiatry, oral/maxillofacial surgery, genitourinary, and plastic/reconstructive surgery. 3. Spinal Fixation and Fusion Systems: The company furnishes a variety of sophisticated spinal devices. These include the Certex spinal fixation system, Spider cervical plating, Axle interspinous fusion, Silex Sacroiliac joint fusion, the Xpress minimally invasive pedicle screw system, and Fortex Pedicle screw systems. Further systems encompass Calix, for use in cervical and thoracolumbar regions, the Axle-X interspinous fusion system, Irix-C for cervical integrated fusion, and the Irix-A Lumbar integrated fusion system. The company underwent a name change in July 2015, transitioning from its former identity as Bacterin International Holdings, Inc. to Xtant Medical Holdings, Inc.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.45
-0.01 (-1.90%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
138.1K
Beta
-0.17
Float Shares
117.66M
Free Float %
84.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.84% | -12.74% | +0.69% | -17.88% | -27.27% | -38.78% | -19.54% | -28.36% | -68.42% | -97.84% | -99.89% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (5 ratings, all time)
Buy
Price Targets & DCF
Current price
0.45
Low
1.50
+233.3%
Consensus
1.50
+233.3%
Median
1.50
+233.3%
High
1.50
+233.3%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 1 |
1.50
+233.3%
|
Quality scores
Altman Z-Score
-0.66
Distress
Piotroski F-Score
7 / 9
Strong
MOAT Score
4 / 10
Developing
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%+14.2% ★ Q1'26: -36.5% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+125.0% ★ Q1'26: -100.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+3.6% Q1'26: -11.1% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+8.0% ★ Q1'26: -14.0% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+12.1% ★ Q1'26: -26.5% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+12.3% Q1'26: -100.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×1.81× Q1'26: -0.63× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 1 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
Dec 2029 1 Rev. Ana. |
Dec 2030 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
59.35M
est: 70.45M (-15.8%)
|
90.00M
est: 89.89M (+0.1%)
|
82.61M
est: 83.29M (-0.8%)
|
72.20M
est: 71.44M (+1.1%)
|
64.68M
est: 65.07M (-0.6%)
|
53.34M
est: 60.50M (-11.8%)
|
55.26M
est: 65.88M (-16.1%)
|
91.30M
est: 110.94M (-17.7%)
|
117.27M
est: 117.52M (-0.2%)
|
133.93M
est: 132.29M (+1.2%)
|
96.73M
96.38M – 97.07M
-26.9% YoY
|
106.04M
103.64M – 108.44M
+9.6% YoY
|
116.32M
116.21M – 116.44M
+9.7% YoY
|
125.93M
124.23M – 127.63M
+8.3% YoY
|
136.98M
135.12M – 138.83M
+8.8% YoY
|
| EBITDA |
-7.09M
est: -1.77M (-299.9%)
|
61.4K
est: -2.26M (+102.7%)
|
-29.31M
est: -2.10M (-1,298.7%)
|
-54.22M
est: -1.80M (-2,916.2%)
|
850.0K
est: -1.64M (+151.9%)
|
1.33M
est: -1.52M (+187.2%)
|
-2.51M
est: -1.66M (-51.6%)
|
5.08M
est: -710.5K (+814.3%)
|
-7.88M
est: -752.6K (-946.7%)
|
15.90M
est: -847.2K (+1,976.1%)
|
-619.5K
-621.7K – -617.3K
+26.9% YoY
|
-679.1K
-694.5K – -663.7K
-9.6% YoY
|
-745.0K
-745.7K – -744.2K
-9.7% YoY
|
-806.5K
-817.4K – -795.6K
-8.3% YoY
|
-877.2K
-889.1K – -865.4K
-8.8% YoY
|
| EBIT |
-11.98M
est: -3.98M (-201.3%)
|
-7.18M
est: -5.07M (-41.5%)
|
-37.71M
est: -4.70M (-702.1%)
|
-59.95M
est: -4.03M (-1,387.1%)
|
-2.35M
est: -3.67M (+36.0%)
|
-751.0K
est: -3.41M (+78.0%)
|
-3.85M
est: -3.72M (-3.7%)
|
1.90M
est: -4.18M (+145.5%)
|
-12.10M
est: -4.43M (-173.3%)
|
10.67M
est: -4.99M (+314.1%)
|
-3.65M
-3.66M – -3.63M
+26.9% YoY
|
-4.00M
-4.09M – -3.91M
-9.6% YoY
|
-4.38M
-4.39M – -4.38M
-9.7% YoY
|
-4.75M
-4.81M – -4.68M
-8.3% YoY
|
-5.16M
-5.23M – -5.09M
-8.8% YoY
|
| Net Income |
-2.17M
est: -2.82B (+99.9%)
|
-19.49M
est: -2.45B (+99.2%)
|
-52.41M
est: -1.44B (+96.4%)
|
-70.10M
est: -179.11M (+60.9%)
|
-8.22M
est: -96.24M (+91.5%)
|
-7.02M
est: -69.51M (+89.9%)
|
-4.85M
est: -129.66M (+96.3%)
|
660.0K
est: -3.85M (+117.1%)
|
-16.45M
est: -17.02M (+3.4%)
|
4.97M
est: 3.97M (+25.3%)
|
1.50M
1.47M – 1.53M
-62.2% YoY
|
-97.5K
-99.2K – -95.8K
-106.5% YoY
|
-82.5K
-247.6K – 82.5K
+15.4% YoY
|
—
— – —
+100.0% YoY
|
—
— – —
|
| SGA |
41.97M
est: 46.67M (-10.1%)
|
60.09M
est: 59.54M (+0.9%)
|
55.84M
est: 55.17M (+1.2%)
|
45.06M
est: 47.32M (-4.8%)
|
43.78M
est: 43.10M (+1.6%)
|
34.49M
est: 40.08M (-14.0%)
|
35.47M
est: 43.64M (-18.7%)
|
64.29M
est: 71.55M (-10.1%)
|
77.91M
est: 75.79M (+2.8%)
|
74.89M
est: 85.32M (-12.2%)
|
62.38M
62.16M – 62.60M
-26.9% YoY
|
68.39M
66.84M – 69.93M
+9.6% YoY
|
75.02M
74.95M – 75.09M
+9.7% YoY
|
81.22M
80.12M – 82.31M
+8.3% YoY
|
88.34M
87.15M – 89.53M
+8.8% YoY
|
| EPS |
-2.62
est: -21.08 (+87.6%)
|
-18.46
est: -18.32 (-0.8%)
|
-34.76
est: -10.77 (-222.7%)
|
-5.97
est: -1.34 (-345.5%)
|
-0.62
est: -0.72 (+13.9%)
|
-0.25
est: -0.52 (+51.9%)
|
-0.06
est: -0.97 (+94.2%)
|
0.01
est: -0.03 (+121.4%)
|
-0.12
est: -0.11 (-5.8%)
|
0.04
est: 0.03 (+51.2%)
|
0.01
0.01 – 0.01
-62.2% YoY
|
0.00
0.00 – 0.00
-106.5% YoY
|
0.00
0.00 – 0.00
+15.4% YoY
|
—
— – —
+100.0% YoY
|
—
— – —
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-13 | BTIG | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-12 | B | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-11 | B | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-06 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-05 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-04 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-01 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-30 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-29 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
11.82M
OE per share TTM
0.08
Owner's Yield
17.65%
Maintenance CapEx ratio
545.79%
Maint CapEx / Avg PPE
9.9%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
8
Total invested
553.0K
Insider transactions (90d)
0
Beneficial owners (>5%)
15
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | OrbiMed Advisors LLC | 72.87M | 84.00% | — | 72.87M | — | 10.00 | IA | Delaware | 2021-04-09 | ↗ |
| 2 | OrbiMed ROF II LLC | 17.05M | 19.70% | — | 17.05M | — | 10.00 | IA | Delaware | 2021-04-09 | ↗ |
| 3 | Stavros G. Vizirgianakis | 7.22M | 6.62% | 7.22M | — | 7.22M | — | IN | — | 2022-09-06 | ↗ |
| 4 | Altium Capital Management, LP | 6.50M | 7.20% | — | 6.50M | — | — | IA, PN | Delaware, United States of America | 2022-02-14 | ↗ |
| 5 | Altium Growth Fund, LP | 6.50M | 7.20% | — | 6.50M | — | — | PN | Delaware, United States of America | 2022-02-14 | ↗ |
| 6 | Altium Growth GP, LLC | 6.50M | 7.20% | — | 6.50M | — | — | OO | Delaware, United States of America | 2022-02-14 | ↗ |
| 7 | Samuel D. Isaly | 2.84M | 13.82% | — | 2.84M | — | 10.00 | IN | United States | 2018-01-17 | ↗ |
| 8 | Andrew J. Schorr | 796.8K | 6.00% | — | 796.8K | — | 796.8K | IN | USA | 2019-02-14 | ↗ |
| 9 | Daniel P. Schorr | 796.8K | 6.00% | — | 796.8K | — | 796.8K | IN | USA | 2019-02-14 | ↗ |
| 10 | Telemetry Investments, L.L.C. | 796.8K | 6.00% | — | 796.8K | — | 796.8K | IA | Delaware | 2019-02-14 | ↗ |
| 11 | Telemetry Securities, L.L.C. | 796.8K | 6.00% | — | — | — | — | PN | Delaware | 2019-02-14 | ↗ |
| 12 | Perkins Capital Managment, Inc. | 684.4K | 3.60% | 590.7K | — | 684.4K | — | IA | A Minnesota | 2019-02-15 | ↗ |
| 13 | Park West Asset Management LLC | — | 0.00% | — | — | — | — | IA | Delaware | 2021-02-16 | ↗ |
| 14 | Park West Investors Master Fund, Limited | — | 0.00% | — | — | — | — | CO | Delaware | 2021-02-16 | ↗ |
| 15 | Peter S. Park | — | 0.00% | — | — | — | — | IN | Delaware | 2021-02-16 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
8
-27 vs prev Q
New positions
0
Closed positions
27
Increased
0
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | NANO CAP NEW MILLENNIUM GROWTH FUND L P | 280.0K +280.0K (+100.0%) | 219.52M +219.5M (+100.0%) | 0.20% +0.201 pp | 0.19% +0.187 pp | USD0.78 +0.0% | 1 qtrs NEW |
| 2 | NANTAHALA CAPITAL MANAGEMENT, LLC | 68.39M +— (+0.0%) | 53.62M +9.2M (+20.8%) | 49.09% +0.000 pp | 1.77% +0.232 pp | USD0.75 +4.0% | 10 qtrs — |
| 3 | AWM INVESTMENT COMPANY, INC. | 6.59M +— (+0.0%) | 5.17M +890.9K (+20.8%) | 4.73% +0.000 pp | 0.50% +0.098 pp | USD0.74 +5.4% | 3 qtrs — |
| 4 | VANGUARD GROUP INC | 2.27M -83.1K (-3.5%) | 1.78M +252.9K (+16.5%) | 1.63% -0.060 pp | 0.00% +0.000 pp | USD0.72 +8.3% | 14 qtrs — |
| 5 | RENAISSANCE TECHNOLOGIES LLC | 919.9K +205.9K (+28.8%) | 721.2K +257.9K (+55.7%) | 0.66% +0.148 pp | 0.00% +0.001 pp | USD1.25 -37.6% | 32 qtrs — |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 491.9K +— (+0.0%) | 385.8K +66.5K (+20.8%) | 0.35% +0.000 pp | 0.00% +0.000 pp | USD0.93 -16.1% | 20 qtrs — |
| 7 | CRESCENT GROVE ADVISORS, LLC | 412.0K +— (+0.0%) | 323.0K +55.7K (+20.8%) | 0.30% +0.000 pp | 0.03% +0.005 pp | USD0.64 +21.9% | 17 qtrs — |
| 8 | HILLSDALE INVESTMENT MANAGEMENT INC. | 362.2K +362.2K (+100.0%) | 284.0K +284.0K (+100.0%) | 0.26% +0.260 pp | 0.01% +0.008 pp | USD0.78 +0.0% | 1 qtrs NEW |
| 9 | CITADEL ADVISORS LLC | 287.8K +207.7K (+259.4%) | 225.6K +173.7K (+334.2%) | 0.21% +0.149 pp | 0.00% +0.000 pp | USD0.70 +11.4% | 13 qtrs — |
| 10 | MILLENNIUM MANAGEMENT LLC | 190.8K -52.1K (-21.4%) | 149.6K -8.0K (-5.1%) | 0.14% -0.037 pp | 0.00% +0.000 pp | USD0.74 +5.4% | 9 qtrs — |
| 11 | ACADIAN ASSET MANAGEMENT LLC | 194.1K +194.1K (+100.0%) | 149.0K +149.0K (+100.0%) | 0.14% +0.139 pp | 0.00% +0.000 pp | USD0.78 +0.0% | 1 qtrs NEW |
| 12 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 164.1K +— (+0.0%) | 128.7K +22.2K (+20.8%) | 0.12% +0.000 pp | 0.00% +0.000 pp | USD1.33 -41.4% | 31 qtrs — |
| 13 | BLACKROCK, INC. | 115.8K -4.5K (-3.8%) | 90.8K +12.7K (+16.3%) | 0.08% -0.003 pp | 0.00% +0.000 pp | USD0.68 +14.7% | 6 qtrs — |
| 14 | MINK BROOK ASSET MANAGEMENT LLC | 109.5K +— (+0.0%) | 85.8K +14.8K (+20.8%) | 0.08% +0.000 pp | 0.05% +0.006 pp | USD0.61 +27.9% | 5 qtrs — |
| 15 | — | 103.0K +103.0K (+100.0%) | 80.8K +80.8K (+100.0%) | 0.07% +0.074 pp | 0.07% +0.068 pp | USD0.78 +0.0% | 1 qtrs NEW |
| 16 | TRADITION WEALTH MANAGEMENT, LLC | 100.3K +100.3K (+100.0%) | 78.6K +78.6K (+100.0%) | 0.07% +0.072 pp | 0.01% +0.006 pp | USD0.78 +0.0% | 1 qtrs NEW |
| 17 | PRIVATE ADVISOR GROUP, LLC | 85.0K -38.0K (-30.9%) | 66.6K -13.2K (-16.5%) | 0.06% -0.027 pp | 0.00% 0.000 pp | USD0.75 +4.0% | 9 qtrs — |
| 18 | TWO SIGMA SECURITIES, LLC | 77.4K +77.4K (+100.0%) | 60.6K +60.6K (+100.0%) | 0.06% +0.056 pp | 0.01% +0.008 pp | USD0.78 +0.0% | 1 qtrs NEW |
| 19 | NORTHERN TRUST CORP | 57.5K -1.2K (-2.0%) | 45.1K +7.0K (+18.3%) | 0.04% -0.001 pp | 0.00% +0.000 pp | USD0.95 -17.9% | 13 qtrs — |
| 20 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 36.2K +36.2K (+100.0%) | 28.3K +28.3K (+100.0%) | 0.03% +0.026 pp | 0.00% +0.000 pp | USD0.78 +0.0% | 10 qtrs — |
| 21 | STATE STREET CORP | 31.3K +— (+0.0%) | 24.5K +4.2K (+20.8%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD1.22 -36.1% | 19 qtrs — |
| 22 | PRUDENTIAL FINANCIAL INC | 23.4K +— (+0.0%) | 18.3K +3.2K (+20.8%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD0.71 +9.9% | 3 qtrs — |
| 23 | LAZARD ASSET MANAGEMENT LLC | 22.7K +22.7K (+100.0%) | 17.8K +17.8K (+100.0%) | 0.02% +0.016 pp | 0.00% +0.000 pp | USD0.78 +0.0% | 1 qtrs NEW |
| 24 | VIRTU FINANCIAL LLC | 20.1K -11.5K (-36.4%) | 16.0K -5.0K (-23.8%) | 0.01% -0.008 pp | 0.00% -0.001 pp | USD0.54 +44.4% | 5 qtrs — |
| 25 | KESTRA ADVISORY SERVICES, LLC | 20.0K +20.0K (+100.0%) | 15.7K +15.7K (+100.0%) | 0.01% +0.014 pp | 0.00% +0.000 pp | USD0.78 +0.0% | 1 qtrs NEW |
| 26 | JANE STREET GROUP, LLC | 19.2K +19.2K (+100.0%) | 15.1K +15.1K (+100.0%) | 0.01% +0.014 pp | 0.00% +0.000 pp | USD0.78 +0.0% | 3 qtrs — |
| 27 | EQUITABLE HOLDINGS, INC. | 11.5K -10.0K (-46.6%) | 9.0K -4.9K (-35.5%) | 0.01% -0.007 pp | 0.00% +0.000 pp | USD0.44 +77.3% | 5 qtrs — |
| 28 | TOWER RESEARCH CAPITAL LLC (TRC) | 4.6K +1.0K (+29.3%) | 3.6K +1.3K (+56.2%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD0.58 +34.5% | 22 qtrs — |
| 29 | MASSMUTUAL TRUST CO FSB/ADV | 2.0K +2.0K (+100.0%) | 1.6K +1.6K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD0.78 +0.0% | 1 qtrs NEW |
| 30 | MORGAN STANLEY | 1.1K +1.1K (+100.0%) | 882.00 +882.0 (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD0.78 +0.0% | 1 qtrs NEW |
| 31 | BANK OF AMERICA CORP /DE/ | 428.00 +35.0 (+8.9%) | 336.00 +82.0 (+32.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.64 +21.9% | 14 qtrs — |
| 32 | HALLMARK CAPITAL MANAGEMENT INC | 298.00 +— (+0.0%) | 234.00 +41.0 (+21.2%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.44 +77.3% | 5 qtrs — |
| 33 | CORNERSTONE PLANNING GROUP LLC | 12.00 -13.0 (-52.0%) | 7.00 -3.8K (-99.8%) | 0.00% +0.000 pp | 0.00% -0.001 pp | USD0.83 -6.0% | 10 qtrs — |
| 34 | UBS GROUP AG | 8.00 -387.0 (-98.0%) | 6.00 -251.0 (-97.7%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD0.63 +23.8% | 3 qtrs — |
| 35 | SBI SECURITIES CO., LTD. | 2.00 +— (+0.0%) | 2.00 +1.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 4 qtrs — |
| 36 | BARCLAYS PLC | — -8.0 (-100.0%) | — -5.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 37 | JPMORGAN CHASE & CO | — -107.0 (-100.0%) | — -69.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 10 qtrs SOLD |
| 38 | PETROS FAMILY WEALTH, LLC | — -20.0K (-100.0%) | — -13.0K (-100.0%) | 0.00% -0.014 pp | 0.00% -0.011 pp | USD— | 5 qtrs SOLD |
| 39 | HRT FINANCIAL LP | — -40.8K (-100.0%) | — -26.0K (-100.0%) | 0.00% -0.029 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 40 | GOLDMAN SACHS GROUP INC | — -21.0K (-100.0%) | — -13.6K (-100.0%) | 0.00% -0.015 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 41 | LARSON FINANCIAL GROUP LLC | — -10.0K (-100.0%) | — -6.5K (-100.0%) | 0.00% -0.007 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 11 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 232.7K | 0.05% |
| 2 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 1.5K | 0.03% |
| 3 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 4.0K | 0.17% |
| 4 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 297.76 | 0.17% |
| 5 | Vanguard Total Stock Market ETF VTI | 0.00% | 688.9K | 0.03% |
| 6 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 1.5K | 0.22% |
| 7 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 821.42 | 0.22% |
| 8 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 331.95 | 0.22% |
| 9 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 36.58 | 0.22% |
| 10 | Vanguard Conservative Income ETF Portfolio VCIP.TO | 0.00% | 5.15 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
1
Shares acquired
—
Shares disposed
8.1K
Cash buys
—
Cash sales
—
Net activity
-8,084
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-15 | Schallenberger Mark A. | Officer | F-InKind | D | Common Stock | 7,709 | 0.58 | 4.5K | 663,157 | D | ↗ |
| 2026-01-15 | Neils Scott C | Officer | F-InKind | D | Common Stock | 8,084 | 0.65 | 5.3K | 843,381 | D | ↗ |
| 2025-11-15 | Vizirgianakis Stavros G. | Director | A-Award | A | Common Stock | 553,797 | 0.00 | — | 7,515,570 | D | ↗ |
| 2025-11-15 | Schallenberger Mark A. | Officer | A-Award | A | Common Stock | 292,253 | 0.00 | — | 670,866 | D | ↗ |
| 2025-11-15 | Neils Scott C | Officer | A-Award | A | Common Stock | 263,291 | 0.00 | — | 851,465 | D | ↗ |
| 2025-11-15 | Lipschultz Tyler | Director | A-Award | A | Common Stock | 158,228 | 0.00 | — | 158,228 | D | ↗ |
| 2025-11-15 | JAIN ABHINAV | Director | A-Award | A | Common Stock | 158,228 | 0.00 | — | 158,228 | D | ↗ |
| 2025-11-15 | Browne Sean E | Director / Officer | A-Award | A | Common Stock | 394,937 | 0.00 | — | 2,575,274 | D | ↗ |
| 2025-11-15 | Beeson Jonn R. | Director | A-Award | A | Common Stock | 158,228 | 0.00 | — | 517,619 | D | ↗ |
| 2025-11-15 | BAKEWELL JOHN K | Director | A-Award | A | Common Stock | 158,228 | 0.00 | — | 914,116 | D | ↗ |
| 2025-08-15 | Neils Scott C | Officer | F-InKind | D | Common Stock | 34,131 | 0.63 | 21.5K | 588,174 | D | ↗ |
| 2025-08-15 | Browne Sean E | Director / Officer | F-InKind | D | Common Stock | 10,605 | 0.63 | 6.7K | 2,180,337 | D | ↗ |
| 2025-08-01 | Lipschultz Tyler | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-08-01 | JAIN ABHINAV | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-04-10 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 17,109,618 | 0.42 | 7.19M | 0 | I | ↗ |
| 2025-04-10 | Nantahala Capital Management, LLC | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 68,394,000 | I | ↗ |
| 2025-01-15 | Neils Scott C | Officer | F-InKind | D | Common Stock | 7,986 | 0.53 | 4.2K | 622,305 | D | ↗ |
| 2024-10-15 | Browne Sean E | Director / Officer | F-InKind | D | Common Stock | 105,442 | 0.59 | 62.2K | 2,190,942 | D | ↗ |
| 2024-08-15 | Vizirgianakis Stavros G. | Director | A-Award | A | Common Stock | 505,405 | 0.00 | — | 6,961,773 | — | ↗ |
| 2024-08-15 | Neils Scott C | Officer | F-InKind | D | Common Stock | 34,132 | 0.60 | 20.5K | 630,291 | — | ↗ |
| 2024-08-15 | McNamara Robert | Director | A-Award | A | Common Stock | 162,162 | 0.00 | — | 754,151 | — | ↗ |
| 2024-08-15 | MITCHELL-KELLER LORI D | Director | A-Award | A | Common Stock | 162,162 | 0.00 | — | 353,124 | — | ↗ |
| 2024-08-15 | Browne Sean E | Director / Officer | F-InKind | D | Common Stock | 10,606 | 0.60 | 6.4K | 2,296,384 | — | ↗ |
| 2024-08-15 | Brandt Kevin D | Officer | F-InKind | D | Common Stock | 56,333 | 0.60 | 33.8K | 943,736 | — | ↗ |
| 2024-08-15 | Beeson Jonn R. | Director | A-Award | A | Common Stock | 162,162 | 0.00 | — | 359,391 | — | ↗ |
| 2024-08-15 | BAKEWELL JOHN K | Director | A-Award | A | Common Stock | 162,162 | 0.00 | — | 755,888 | — | ↗ |
| 2024-04-03 | Schallenberger Mark A. | Officer | A-Award | A | Common Stock | 177,551 | 0.00 | — | 382,695 | — | ↗ |
| 2024-04-03 | Neils Scott C | Officer | A-Award | A | Common Stock | 177,551 | 0.00 | — | 664,423 | — | ↗ |
| 2024-04-03 | Browne Sean E | Director / Officer | A-Award | A | Common Stock | 731,632 | 0.00 | — | 2,306,990 | — | ↗ |
| 2024-04-03 | Brandt Kevin D | Officer | A-Award | A | Common Stock | 184,209 | 0.00 | — | 1,000,069 | — | ↗ |
| 2024-01-16 | Neils Scott C | Officer | F-InKind | D | Common Stock | 7,986 | 1.09 | 8.7K | 486,872 | — | ↗ |
| 2023-11-17 | Brandt Kevin D | Officer | P-Purchase | A | Common Stock | 41,670 | 1.20 | 49.8K | 815,860 | — | ↗ |
| 2023-10-15 | Browne Sean E | Director / Officer | F-InKind | D | Common Stock | 105,442 | 1.08 | 113.9K | 1,575,358 | — | ↗ |
| 2023-08-15 | Vizirgianakis Stavros G. | Director | A-Award | A | Stock Option (right to buy) | 42,345 | 1.20 | 50.8K | 42,345 | — | ↗ |
| 2023-08-15 | Schallenberger Mark A. | Officer | A-Award | A | Stock Option (right to buy) | 135,501 | 1.20 | 162.6K | 135,501 | — | ↗ |
| 2023-08-15 | Neils Scott C | Officer | A-Award | A | Stock Option (right to buy) | 135,501 | 1.20 | 162.6K | 135,501 | — | ↗ |
| 2023-08-15 | McNamara Robert | Director | A-Award | A | Stock Option (right to buy) | 28,230 | 1.20 | 33.9K | 28,230 | — | ↗ |
| 2023-08-15 | MITCHELL-KELLER LORI D | Director | A-Award | A | Stock Option (right to buy) | 28,230 | 1.20 | 33.9K | 28,230 | — | ↗ |
| 2023-08-15 | Browne Sean E | Director / Officer | A-Award | A | Stock Option (right to buy) | 203,252 | 1.20 | 243.9K | 203,252 | — | ↗ |
| 2023-08-15 | Brandt Kevin D | Officer | A-Award | A | Stock Option (right to buy) | 140,583 | 1.20 | 168.7K | 140,583 | — | ↗ |
| 2023-08-15 | Beeson Jonn R. | Director | A-Award | A | Stock Option (right to buy) | 28,230 | 1.20 | 33.9K | 28,230 | — | ↗ |
| 2023-08-15 | BAKEWELL JOHN K | Director | A-Award | A | Stock Option (right to buy) | 28,230 | 1.20 | 33.9K | 28,230 | — | ↗ |
| 2023-06-15 | MITCHELL-KELLER LORI D | Director | A-Award | A | Common Stock | 45,782 | 0.00 | — | 45,782 | — | ↗ |
| 2023-05-16 | MITCHELL-KELLER LORI D | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-05-15 | Beeson Jonn R. | Director | A-Award | A | Common Stock | 52,049 | 0.00 | — | 52,049 | — | ↗ |
| 2023-05-01 | Beeson Jonn R. | Director | — | I | Common Stock, $0.000001 par value | 0 | 0.00 | — | 1,015,272 | — | ↗ |
| 2023-02-15 | Schallenberger Mark A. | Officer | A-Award | A | Stock Option (right to buy) | 105,000 | 0.77 | 80.9K | 105,000 | — | ↗ |
| 2023-01-18 | Neils Scott C | Officer | S-Sale | D | Common Stock, $0.000001 par value | 8,673 | 0.61 | 5.3K | 403,960 | — | ↗ |
| 2023-01-16 | Schallenberger Mark A. | Officer | — | D | Common Stock, $0.000001 par value | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-11-15 | Vizirgianakis Stavros G. | Director | A-Award | A | Common Stock, $0.000001 par value | 144,639 | 0.00 | — | 5,995,355 | — | ↗ |
| 2022-10-19 | Browne Sean E | Officer | S-Sale | D | Common Stock, $0.000001 par value | 51,100 | 0.62 | 31.8K | 1,506,584 | — | ↗ |
| 2022-10-18 | Browne Sean E | Officer | S-Sale | D | Common Stock, $0.000001 par value | 80,000 | 0.68 | 54.0K | 1,557,684 | — | ↗ |
| 2022-10-07 | Vizirgianakis Stavros G. | Director | P-Purchase | A | Common Stock, $0.000001 par value | 2,264,861 | 0.48 | 1.09M | 5,850,716 | — | ↗ |
| 2022-08-25 | Vizirgianakis Stavros G. | Director | A-Award | A | Common Stock, $0.000001 par value | 70,776 | 0.00 | — | 3,585,855 | — | ↗ |
| 2022-08-25 | Beeson Jonn R. | Director | — | I | Warrant | 253,818 | 0.48 | 121.8K | 0 | — | ↗ |
| 2022-08-17 | Brandt Kevin D | Officer | S-Sale | D | Common Stock, $0.000001 par value | 4,300 | 0.48 | 2.0K | 703,571 | — | ↗ |
| 2022-08-15 | Rizzo Matthew | Director | A-Award | A | Common Stock, $0.000001 par value | 215,415 | 0.00 | — | 215,415 | — | ↗ |
| 2022-08-15 | Peters Jeffrey J | Director | A-Award | A | Common Stock, $0.000001 par value | 215,415 | 0.00 | — | 448,546 | — | ↗ |
| 2022-08-15 | Orbimed ROF II LLC | Director | J-Other | A | Common Stock, $0.000001 par value | 215,415 | 0.00 | — | 215,415 | — | ↗ |
| 2022-08-15 | ORBIMED ADVISORS LLC | Director / 10% Owner | J-Other | A | Common Stock, $0.000001 par value | 215,415 | 0.00 | — | 215,415 | — | ↗ |
| 2022-08-15 | Neils Scott C | Officer | S-Sale | D | Common Stock, $0.000001 par value | 1,270 | 0.48 | 605.03 | 412,633 | — | ↗ |
| 2022-08-15 | McNamara Robert | Director | A-Award | A | Common Stock, $0.000001 par value | 215,415 | 0.00 | — | 446,809 | — | ↗ |
| 2022-08-15 | Eggenberg Michael | Director | A-Award | A | Common Stock, $0.000001 par value | 215,415 | 0.00 | — | 215,415 | — | ↗ |
| 2022-08-15 | Brandt Kevin D | Officer | S-Sale | D | Common Stock, $0.000001 par value | 18,700 | 0.49 | 9.2K | 707,871 | — | ↗ |
| 2022-08-15 | BAKEWELL JOHN K | Director | A-Award | A | Common Stock, $0.000001 par value | 215,415 | 0.00 | — | 448,546 | — | ↗ |
| 2022-01-15 | Neils Scott C | Officer | A-Award | A | Common Stock, $0.000001 par value | 88,983 | 0.00 | — | 167,108 | — | ↗ |
| 2022-01-03 | Neils Scott C | Officer | — | D | Employee Stock Option (right to buy) | 20,508 | 1.80 | 36.9K | 0 | — | ↗ |
| 2021-10-15 | Browne Sean E | Director / Officer | F-InKind | D | Common Stock, $0.000001 par value | 160,219 | 1.11 | 177.8K | 1,637,684 | — | ↗ |
| 2021-08-15 | Rizzo Matthew | Director | A-Award | A | Common Stock | 85,337 | 0.00 | — | 120,549 | — | ↗ |
| 2021-08-15 | Peters Jeffrey J | Director | A-Award | A | Common Stock, $0.000001 par value | 85,337 | 0.00 | — | 233,131 | — | ↗ |
| 2021-08-15 | ORBIMED ADVISORS LLC | Director / 10% Owner | J-Other | A | Common Stock | 85,337 | 0.00 | — | 120,549 | — | ↗ |
| 2021-08-15 | McNamara Robert | Director | A-Award | A | Common Stock, $0.000001 par value | 85,337 | 0.00 | — | 231,394 | — | ↗ |
| 2021-08-15 | JENSEN GREG | Officer | A-Award | A | Stock Option (right to buy) | 192,308 | 1.27 | 244.2K | 192,308 | — | ↗ |
| 2021-08-15 | Eggenberg Michael | Director | A-Award | A | Common Stock | 85,337 | 0.00 | — | 120,549 | — | ↗ |
| 2021-08-15 | Brandt Kevin D | Officer | A-Award | A | Stock Option (right to buy) | 199,519 | 1.27 | 253.4K | 199,519 | — | ↗ |
| 2021-08-15 | BAKEWELL JOHN K | Director | A-Award | A | Common Stock, $0.000001 par value | 85,337 | 0.00 | — | 233,131 | — | ↗ |
| 2021-07-09 | Brandt Kevin D | Officer | F-InKind | D | Common Stock, $0.000001 par value | 8,800 | 1.74 | 15.3K | 161,552 | — | ↗ |
| 2020-11-17 | Rizzo Matthew | Director / 10% Owner | X-InTheMoney | A | Common Stock | 765,992 | 0.01 | 7.7K | 53,468,376 | — | ↗ |
| 2020-11-17 | ORBIMED ADVISORS LLC | Director / 10% Owner | X-InTheMoney | A | Common Stock | 868,016 | 0.01 | 8.7K | 17,036,720 | — | ↗ |
| 2020-11-17 | Eggenberg Michael | Director / 10% Owner | X-InTheMoney | A | Common Stock | 434,008 | 0.01 | 4.3K | 15,734,696 | — | ↗ |
| 2020-11-15 | Browne Sean E | Director / Officer | A-Award | A | Common Stock, $0.000001 par value | 1,468,859 | 0.00 | — | 1,797,903 | — | ↗ |
| 2020-10-01 | Rizzo Matthew | Director / 10% Owner | A-Award | A | Common Stock | 46,784,775 | 1.07 | 50.06M | 52,702,384 | — | ↗ |
| 2020-10-01 | ORBIMED ADVISORS LLC | Director / 10% Owner | A-Award | A | Common Stock | 11,969,619 | 1.07 | 12.81M | 15,300,688 | — | ↗ |
| 2020-10-01 | Eggenberg Michael | Director / 10% Owner | A-Award | A | Common Stock | 11,969,619 | 1.07 | 12.81M | 15,300,688 | — | ↗ |
| 2020-08-15 | JENSEN GREG | Officer | A-Award | A | Common Stock, $0.000001 par value | 95,183 | 0.00 | — | 129,081 | — | ↗ |
| 2020-08-15 | Brandt Kevin D | Officer | A-Award | A | Common Stock, $0.000001 par value | 95,183 | 0.00 | — | 170,352 | — | ↗ |
| 2020-05-06 | Rizzo Matthew | Director / 10% Owner | A-Award | A | Warrant (right to buy) | 1,531,984 | 0.01 | 15.3K | 1,531,984 | — | ↗ |
| 2020-05-06 | ORBIMED ADVISORS LLC | Director / 10% Owner | A-Award | A | Warrant (right to buy) | 1,531,984 | 0.01 | 15.3K | 1,531,984 | — | ↗ |
| 2020-05-06 | Eggenberg Michael | Director / 10% Owner | A-Award | A | Warrant (right to buy) | 1,531,984 | 0.01 | 15.3K | 1,531,984 | — | ↗ |
| 2020-02-05 | Rizzo Matthew | Director / 10% Owner | A-Award | A | Common Stock, $0.000001 par value | 70,423 | 0.00 | — | 91,256 | — | ↗ |
| 2020-02-05 | Peters Jeffrey J | Director | A-Award | A | Common Stock, $0.000001 par value | 116,197 | 0.00 | — | 147,794 | — | ↗ |
| 2020-02-05 | ORBIMED ADVISORS LLC | Director / 10% Owner | J-Other | A | Common Stock, $0.000001 par value | 70,423 | 0.00 | — | 91,256 | — | ↗ |
| 2020-02-05 | McNamara Robert | Director | A-Award | A | Common Stock, $0.000001 par value | 116,197 | 0.00 | — | 146,057 | — | ↗ |
| 2020-02-05 | Eggenberg Michael | Director / 10% Owner | A-Award | A | Common Stock, $0.000001 par value | 70,423 | 0.00 | — | 91,256 | — | ↗ |
| 2020-02-05 | BAKEWELL JOHN K | Director | A-Award | A | Common Stock, $0.000001 par value | 116,197 | 0.00 | — | 147,794 | — | ↗ |
| 2019-10-30 | Rizzo Matthew | Director / 10% Owner | A-Award | A | Common Stock, $0.000001 par value | 20,833 | 0.00 | — | 20,833 | — | ↗ |
| 2019-10-30 | ORBIMED ADVISORS LLC | Director / 10% Owner | J-Other | A | Common Stock, $0.000001 par value | 20,833 | 0.00 | — | 20,833 | — | ↗ |
| 2019-10-30 | Eggenberg Michael | Director / 10% Owner | A-Award | A | Common Stock, $0.000001 par value | 20,833 | 0.00 | — | 20,833 | — | ↗ |
| 2019-10-15 | Browne Sean E | Officer | A-Award | A | Common Stock, $0.000001 par value | 329,044 | 0.00 | — | 329,044 | — | ↗ |
| 2019-10-07 | Browne Sean E | Officer | — | D | Common Stock, $0.000001 par value | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-09-24 | Peters Jeffrey J | Director | A-Award | A | Common Stock, $0.000001 par value | 5,555 | 0.00 | — | 31,597 | — | ↗ |
| 2019-09-24 | McNamara Robert | Director | A-Award | A | Common Stock, $0.000001 par value | 9,027 | 0.00 | — | 29,860 | — | ↗ |
| 2019-09-24 | BAKEWELL JOHN K | Director | A-Award | A | Common Stock, $0.000001 par value | 5,555 | 0.00 | — | 31,597 | — | ↗ |
| 2019-08-15 | JENSEN GREG | Officer | A-Award | A | Stock Option (right to buy) | 39,063 | 2.76 | 107.8K | 39,063 | — | ↗ |
| 2019-08-15 | Brandt Kevin D | Officer | A-Award | A | Common Stock, $0.000001 par value | 35,169 | 0.00 | — | 75,169 | — | ↗ |
| 2019-04-01 | Rizzo Matthew | Director / 10% Owner | A-Award | A | Warrant (right to buy) | 434,008 | 0.01 | 4.3K | 434,008 | — | ↗ |
| 2019-04-01 | ORBIMED ADVISORS LLC | Director / 10% Owner | A-Award | A | Warrant (right to buy) | 434,008 | 0.01 | 4.3K | 434,008 | — | ↗ |
| 2019-04-01 | Eggenberg Michael | Director / 10% Owner | A-Award | A | Warrant (right to buy) | 434,008 | 0.01 | 4.3K | 434,008 | — | ↗ |
| 2019-02-11 | JENSEN GREG | Officer | — | D | Common Stock, $0.000001 par value | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-01-15 | Berlin Ronald G. | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 2.24 | 224.0K | 100,000 | — | ↗ |
| 2019-01-01 | Berlin Ronald G. | Officer | — | D | Common Stock, $0.000001 par value | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-10-15 | Mainelli Michael | Director / Officer | A-Award | A | Stock Option (right to buy) | 240,000 | 3.22 | 772.8K | 240,000 | — | ↗ |
| 2018-09-17 | Rizzo Matthew | Director / 10% Owner | A-Award | A | Warrant (right to buy) | 765,992 | 0.01 | 7.7K | 765,992 | — | ↗ |
| 2018-09-17 | ORBIMED ADVISORS LLC | Director / 10% Owner | A-Award | A | Warrant (right to buy) | 765,992 | 0.01 | 7.7K | 765,992 | — | ↗ |
| 2018-09-17 | Eggenberg Michael | Director / 10% Owner | A-Award | A | Warrant (right to buy) | 765,992 | 0.01 | 7.7K | 765,992 | — | ↗ |
| 2018-09-15 | Lenzen Kathie J. | Officer | A-Award | A | Stock Option (right to buy) | 130,000 | 4.66 | 605.8K | 130,000 | — | ↗ |
| 2018-08-20 | Lenzen Kathie J. | Officer | — | D | Common Stock, $0.000001 par value | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-08-15 | Peters Jeffrey J | Director | A-Award | A | Common Stock, $0.000001 par value | 26,042 | 0.00 | — | 26,042 | — | ↗ |
| 2018-08-15 | O'Connell Carl | Officer | A-Award | A | Stock Option (right to buy) | 200,000 | 6.20 | 1.24M | 200,000 | — | ↗ |
| 2018-08-15 | Brandt Kevin D | Officer | A-Award | A | Stock Option (right to buy) | 30,770 | 6.20 | 190.8K | 30,770 | — | ↗ |
| 2018-07-09 | Brandt Kevin D | Officer | — | D | Common Stock, $0.000001 par value | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-05-02 | McNamara Robert | Director | A-Award | A | Common Stock | 20,833 | 0.00 | — | 20,833 | — | ↗ |
| 2018-04-09 | BAKEWELL JOHN K | Director | A-Award | A | Common Stock | 26,042 | 0.00 | — | 26,042 | — | ↗ |
| 2018-04-08 | Mainelli Michael | Director | A-Award | A | Common Stock | 20,833 | 0.00 | — | 20,833 | — | ↗ |
| 2018-02-14 | Rizzo Matthew | Director / 10% Owner | D-Return | D | Convertible Note | 0 | 46.56 | — | 0 | — | ↗ |
| 2018-02-14 | ORBIMED ADVISORS LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 603,687 | 7.20 | 4.35M | 5,890,884 | — | ↗ |
| 2018-02-14 | Eggenberg Michael | Director / 10% Owner | P-Purchase | A | Common Stock | 342,132 | 7.20 | 2.46M | 3,316,128 | — | ↗ |
| 2018-02-13 | Rizzo Matthew | Director / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 1,927,977 | — | ↗ |
| 2018-02-13 | Peters Jeffrey J | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-02-13 | McNamara Robert | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-02-13 | Mainelli Michael | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-02-13 | Eggenberg Michael | Director / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 1,927,977 | — | ↗ |
| 2018-02-13 | BAKEWELL JOHN K | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-01-17 | ORBIMED ADVISORS LLC | 10% Owner | — | I | Convertible Note | 0 | 3.88 | — | 0 | — | ↗ |
| 2017-07-25 | TIMKO ERIC BERNARD | Director | A-Award | A | Common Stock | 51,948 | 0.00 | — | 51,948 | — | ↗ |
| 2017-07-25 | Swanson Kent L | Director | A-Award | A | Common Stock | 51,948 | 0.00 | — | 318,641 | — | ↗ |
| 2017-07-25 | Mazzocchi Rudy A | Director | A-Award | A | Common Stock | 51,948 | 0.00 | — | 51,948 | — | ↗ |
| 2017-07-25 | LOPACH MICHAEL A | Director | A-Award | A | Common Stock | 51,948 | 0.00 | — | 95,335 | — | ↗ |
| 2017-07-25 | DEEDRICK JOHN ARTHUR | Director | A-Award | A | Common Stock | 51,948 | 0.00 | — | 100,434 | — | ↗ |
| 2017-07-25 | BUCKMAN PAUL | Director | A-Award | A | Common Stock | 51,948 | 0.00 | — | 72,049 | — | ↗ |
| 2016-11-17 | Swanson Kent L | Director | X-InTheMoney | A | Warrants (right to buy) | 150,000 | 0.90 | 135.0K | 150,000 | — | ↗ |
| 2016-11-17 | Goldberger Daniel S | Director / Officer | X-InTheMoney | A | Warrants (right to buy) | 120,000 | 0.90 | 108.0K | 120,000 | — | ↗ |
| 2016-11-14 | Swanson Kent L | Director | X-InTheMoney | D | Subscription Rights (right to receive) | 150,000 | 0.75 | 112.5K | 0 | — | ↗ |
| 2016-11-14 | Goldberger Daniel S | Director / Officer | X-InTheMoney | D | Subscription Rights (right to receive) | 120,000 | 0.75 | 90.0K | 0 | — | ↗ |
| 2016-10-06 | O'Connell Carl | Officer | A-Award | A | Stock Option | 300,000 | 1.11 | 333.0K | 300,000 | — | ↗ |
| 2016-07-05 | TIMKO ERIC BERNARD | Director | A-Award | A | Stock Option | 29,700 | 1.99 | 59.1K | 29,700 | — | ↗ |
| 2016-07-05 | Swanson Kent L | Director | A-Award | A | Common Stock | 20,101 | 0.00 | — | 116,693 | — | ↗ |
| 2016-07-05 | Mazzocchi Rudy A | Director | A-Award | A | Stock Option | 29,700 | 1.99 | 59.1K | 29,700 | — | ↗ |
| 2016-07-05 | LOPACH MICHAEL A | Director | A-Award | A | Common Stock | 20,101 | 0.00 | — | 43,387 | — | ↗ |
| 2016-07-05 | DEEDRICK JOHN ARTHUR | Director | A-Award | A | Common Stock | 20,101 | 0.00 | — | 48,486 | — | ↗ |
| 2016-07-05 | BUCKMAN PAUL | Director | A-Award | A | Common Stock | 20,101 | 0.00 | — | 20,101 | — | ↗ |
| 2016-07-02 | TIMKO ERIC BERNARD | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-07-02 | Mazzocchi Rudy A | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-07-02 | Kirschman David Louis | Director / 10% Owner | D-Return | D | Restricted Stock Unit | 40,000 | 0.00 | — | 0 | — | ↗ |
| 2016-07-02 | BUCKMAN PAUL | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-07-01 | WICKWIRE JON M. | — | M-Exempt | A | Common Stock | 11,764 | 0.00 | — | 43,011 | — | ↗ |
| 2016-07-01 | Swanson Kent L | Director | M-Exempt | D | Restricted Stock Unit | 11,764 | 0.00 | — | 0 | — | ↗ |
| 2016-07-01 | LOPACH MICHAEL A | Director | M-Exempt | D | Restricted Stock Unit | 11,764 | 0.00 | — | 0 | — | ↗ |
| 2016-07-01 | Goodman David | — | M-Exempt | D | Restricted Stock Unit | 11,764 | 0.00 | — | 0 | — | ↗ |
| 2016-07-01 | DEEDRICK JOHN ARTHUR | Director | M-Exempt | D | Restricted Stock Unit | 11,764 | 0.00 | — | 0 | — | ↗ |
| 2016-05-09 | Goldberger Daniel S | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 2.34 | 11.7K | 86,522 | — | ↗ |
| 2015-12-18 | Swanson Kent L | Director | L-Small | A | Common Stock | 1,000 | 2.80 | 2.8K | 84,828 | — | ↗ |
| 2015-12-14 | Swanson Kent L | Director | L-Small | A | Common Stock | 552 | 3.19 | 1.8K | 83,828 | — | ↗ |
| 2015-12-04 | Swanson Kent L | Director | L-Small | A | Common Stock | 148 | 2.81 | 415.88 | 83,276 | — | ↗ |
| 2015-12-03 | Swanson Kent L | Director | P-Purchase | A | Common Stock | 1,000 | 2.83 | 2.8K | 83,128 | — | ↗ |
| 2015-12-01 | Swanson Kent L | Director | P-Purchase | A | Common Stock | 1,000 | 2.85 | 2.9K | 80,828 | — | ↗ |
| 2015-11-20 | Swanson Kent L | Director | P-Purchase | A | Common Stock | 4,976 | 3.00 | 14.9K | 79,828 | — | ↗ |
| 2015-11-20 | Kirschman David Louis | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 1,000 | 2.94 | 2.9K | 1,700,063 | — | ↗ |
| 2015-11-19 | Swanson Kent L | Director | P-Purchase | A | Common Stock | 24 | 2.90 | 69.60 | 74,852 | — | ↗ |
| 2015-11-19 | Kirschman David Louis | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 1,000 | 2.94 | 2.9K | 1,699,063 | — | ↗ |
| 2015-11-18 | Kirschman David Louis | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 1,000 | 2.86 | 2.9K | 1,698,063 | — | ↗ |
| 2015-11-16 | Goldberger Daniel S | Director / Officer | P-Purchase | A | Common Stock | 3,000 | 2.80 | 8.4K | 15,510 | — | ↗ |
| 2015-10-12 | Kirschman David Louis | Director / Officer / 10% Owner | A-Award | A | Restricted Stock Unit | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2015-09-04 | WICKWIRE JON M. | Director | P-Purchase | A | Common Stock | 10,869 | 3.68 | 40.0K | 31,247 | — | ↗ |
| 2015-09-04 | Swanson Kent L | Director | P-Purchase | A | Common Stock | 30,000 | 3.68 | 110.4K | 74,828 | — | ↗ |
| 2015-09-04 | LOPACH MICHAEL A | Director | P-Purchase | A | Common Stock | 10,869 | 3.68 | 40.0K | 14,258 | — | ↗ |
| 2015-09-04 | Goldberger Daniel S | Director / Officer | P-Purchase | A | Common Stock | 81,522 | 3.68 | 300.0K | 81,522 | — | ↗ |
| 2015-09-04 | DEEDRICK JOHN ARTHUR | Director | P-Purchase | A | Common Stock | 6,793 | 3.68 | 25.0K | 16,621 | — | ↗ |
| 2015-07-31 | Kirschman David Louis | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 1,697,063 | — | ↗ |
| 2015-07-31 | Hemmelgarn Kenneth J. Jr. | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 1,272,796 | — | ↗ |
| 2015-07-31 | Hemmelgarn Brian J. | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 1,272,796 | — | ↗ |
| 2015-07-01 | WICKWIRE JON M. | Director | M-Exempt | A | Common Stock | 9,828 | 0.00 | — | 20,378 | — | ↗ |
| 2015-07-01 | Swanson Kent L | Director | A-Award | A | Restricted Stock Unit | 11,764 | 0.00 | — | 11,764 | — | ↗ |
| 2015-07-01 | LOPACH MICHAEL A | Director | M-Exempt | D | Restricted Stock Unit | 9,828 | 0.00 | — | 0 | — | ↗ |
| 2015-07-01 | Goodman David | Director | A-Award | A | Restricted Stock Unit | 11,764 | 0.00 | — | 11,764 | — | ↗ |
| 2015-07-01 | DEEDRICK JOHN ARTHUR | Director | M-Exempt | A | Common Stock | 9,828 | 0.00 | — | 9,828 | — | ↗ |
| 2014-11-10 | WICKWIRE JON M. | Director | A-Award | A | Restricted Stock Unit | 9,828 | 0.00 | — | 9,828 | — | ↗ |
| 2014-11-10 | Swanson Kent L | Director | A-Award | A | Restricted Stock Unit | 9,828 | 0.00 | — | 9,828 | — | ↗ |
| 2014-11-10 | LOPACH MICHAEL A | Director | A-Award | A | Restricted Stock Unit | 9,828 | 0.00 | — | 9,828 | — | ↗ |
| 2014-11-10 | DEEDRICK JOHN ARTHUR | Director | A-Award | A | Restricted Stock Unit | 9,828 | 0.00 | — | 9,828 | — | ↗ |
| 2014-09-04 | JUDA GREGORY ALEXANDER | Officer | A-Award | A | Employee Stock Option | 6,000 | 5.01 | 30.1K | 6,000 | — | ↗ |
| 2014-09-04 | HOLMES DARREL LEE | Officer | A-Award | A | Employee Stock Option | 9,000 | 5.01 | 45.1K | 9,000 | — | ↗ |
| 2014-09-04 | GANDOLFO JOHN P | Officer | A-Award | A | Employee Stock Option | 30,000 | 5.01 | 150.3K | 30,000 | — | ↗ |
| 2014-08-15 | Goodman David | Director | A-Award | A | Stock Option | 5,000 | 4.80 | 24.0K | 5,000 | — | ↗ |
| 2014-08-13 | Goodman David | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-07-24 | JUDA GREGORY ALEXANDER | Officer | D-Return | D | Employee Stock Option | 24,999 | 1.34 | 33.5K | 0 | — | ↗ |
| 2014-07-18 | HOLMES DARREL LEE | Officer | D-Return | D | Employee Stock Option | 15,000 | 1.50 | 22.5K | 0 | — | ↗ |
| 2014-07-01 | DI SILVIO ROBERT M | Officer | — | D | Common Stock | 0 | 0.00 | — | 11,981 | — | ↗ |
| 2014-06-10 | HOLMES DARREL LEE | Officer | S-Sale | D | Common Stock | 50,000 | 0.74 | 37.0K | 11,656 | — | ↗ |
| 2014-06-05 | GANDOLFO JOHN P | Officer | D-Return | D | Employee Stock Option | 70,000 | 2.36 | 165.2K | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
49.2K
Shares Outstanding
140.07M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Sean E. Browne President and Chief Executive Officer | 617.5K | — | 1.81M | — | — | 37.1K | 2.46M | 73.41% | ↗ |
| 2 | 2024 | Kevin D. Brandt Former Chief Commercial Officer | 315.7K | — | 455.0K | — | — | 460.0K | 1.23M | 36.97% | ↗ |
| 3 | 2024 | Scott C. Neils Chief Financial Officer | 411.7K | — | 438.6K | — | — | 33.3K | 883.5K | 49.64% | ↗ |
| 4 | 2024 | Mark A. Schallenberger Chief Operating Officer | 411.7K | — | 428.5K | — | — | 38.8K | 879.0K | 48.75% | ↗ |
| 5 | 2023 | Sean E. Browne President and Chief Executive Officer | 600.0K | — | 209.1K | 209.3K | 664.6K | 29.3K | 1.71M | 24.43% | ↗ |
| 6 | 2023 | Mark A. Schallenberger Chief Operations Officer | 400.0K | — | 205.1K | 208.3K | 221.5K | 139.7K | 1.17M | 35.19% | ↗ |
| 7 | 2023 | Mark A. Schallenberger Chief Operating Officer | 400.0K | — | 205.1K | 208.3K | 221.5K | 139.7K | 1.17M | 35.19% | ↗ |
| 8 | 2023 | Kevin D. Brandt Former Chief Commercial Officer | 415.0K | — | 144.6K | 144.7K | 229.8K | 13.2K | 947.4K | 30.54% | ↗ |
| 9 | 2023 | Kevin D. Brandt Chief Commercial Officer | 415.0K | — | 144.6K | 144.7K | 229.8K | 13.2K | 947.4K | 30.54% | ↗ |
| 10 | 2023 | Scott C. Neils Chief Financial Officer | 400.0K | — | 139.4K | 139.5K | 221.5K | 37.4K | 937.9K | 29.74% | ↗ |
| 11 | 2022 | Sean E. Browne President and Chief Executive Officer | 600.0K | — | — | — | 416.4K | 44.2K | 1.06M | 0.00% | ↗ |
| 12 | 2022 | Kevin D. Brandt Chief Commercial Officer | 415.0K | — | 213.2K | — | 144.0K | 6.3K | 778.5K | 27.39% | ↗ |
| 13 | 2022 | Scott C. Neils Chief Financial Officer | 367.0K | — | 188.6K | 60.0K | 124.3K | 26.5K | 766.5K | 32.44% | ↗ |
| 14 | 2021 | Greg Jensen Former Vice President, Finance and Chief Financial Officer | 393.8K | — | 198.4K | 206.5K | 100.2K | 55.9K | 954.9K | 42.41% | ↗ |
| 15 | 2021 | Kevin D. Brandt Chief Commercial Officer | 408.6K | — | 205.9K | 214.3K | 85.2K | 10.0K | 924.0K | 45.47% | ↗ |
| 16 | 2021 | Sean E. Browne President and Chief Executive Officer | 590.2K | — | — | — | 201.9K | 39.4K | 831.5K | 0.00% | ↗ |
| 17 | 2020 | Sean E. Browne President and Chief Executive Officer | 603.7K | — | 1.85M | 1.51M | 510.0K | 76.1K | 4.55M | 73.84% | ↗ |
| 18 | 2020 | Greg Jensen Vice President, Finance and Chief Financial Officer | 402.5K | — | 107.6K | 108.5K | 170.0K | 72.6K | 861.1K | 25.09% | ↗ |
| 19 | 2020 | Greg Jensen Former Vice President, Finance and Chief Financial Officer | 402.5K | — | 107.6K | 108.5K | 170.0K | 72.6K | 861.1K | 25.09% | ↗ |
| 20 | 2020 | Kevin D. Brandt Chief Commercial Officer | 417.6K | — | 107.6K | 108.5K | 176.4K | 11.4K | 821.4K | 26.30% | ↗ |
| 21 | 2019 | Sean E. Browne President and Chief Executive Officer | 115.7K | — | 888.4K | 688.1K | 150.0K | 10.0K | 1.85M | 85.11% | ↗ |
| 22 | 2019 | Kevin D. Brandt Chief Commercial Officer | 398.1K | 90.0K | 97.1K | 85.5K | 124.1K | 17.4K | 812.3K | 22.48% | ↗ |
| 23 | 2019 | Greg Jensen Vice President, Finance and Chief Financial Officer | 336.0K | — | 93.6K | 82.1K | 114.4K | 63.2K | 689.2K | 25.48% | ↗ |
| 24 | 2019 | Ronald G. Berlin Vice President, Chief Operations Officer and General Manager | 362.7K | 50.0K | — | 121.5K | 109.9K | 11.9K | 656.0K | 18.52% | ↗ |
| 25 | 2019 | Michael Mainelli Former Interim Chief Executive Officer | 184.1K | — | — | — | — | 10.9K | 194.9K | 0.00% | ↗ |
| 26 | 2018 | Carl O’Connell Former Chief Executive Officer | 578.8K | 155.0K | — | 1.07M | — | — | 1.81M | 59.40% | ↗ |
| 27 | 2018 | Michael Mainelli Former Interim Chief Executive Officer | 92.9K | — | 153.3K | 670.6K | 90.9K | 89.9K | 1.10M | 75.07% | ↗ |
| 28 | 2018 | Kevin D. Brandt Chief Commercial Officer | 176.9K | — | 248.0K | 165.2K | 76.2K | — | 666.3K | 62.02% | ↗ |
| 29 | 2018 | Kathie J. Lenzen Former Chief Financial Officer | 104.6K | — | — | 524.8K | — | — | 629.4K | 83.38% | ↗ |
| 30 | 2017 | Carl O’Connell Former Chief Executive Officer | 502.7K | 55.0K | — | — | — | — | 557.7K | 0.00% | ↗ |
| 31 | 2017 | Carl O’Connell Chief Executive Officer | 502.7K | 55.0K | — | — | — | — | 557.7K | 0.00% | ↗ |
| 32 | 2017 | John Gandolfo Former Chief Financial Officer | 298.9K | 36.0K | — | — | — | 129.8K | 464.7K | 0.00% | ↗ |
| 33 | 2017 | John Gandolfo Chief Financial Officer (From July 6, 2010 to August 25,2017) | 298.9K | 36.0K | — | — | — | 129.8K | 464.7K | 0.00% | ↗ |
| 34 | 2017 | Kevin O’Dare Area Vice President-East | 200.0K | — | — | — | — | 147.7K | 347.7K | 0.00% | ↗ |
| 35 | 2017 | Christopher Valois Vice President Sales and Marketing | 296.0K | 18.9K | — | — | — | — | 314.9K | 0.00% | ↗ |
| 36 | 2017 | Daniel Goldberger Former Chief Executive Officer | 154.3K | — | — | — | — | 130.0K | 284.3K | 0.00% | ↗ |
| 37 | 2017 | Daniel Goldberger Chief Executive Officer | 154.3K | — | — | — | — | 130.0K | 284.3K | 0.00% | ↗ |
| 38 | 2016 | Daniel Goldberger Former Chief Executive Officer | 518.5K | — | — | — | — | — | 518.5K | 0.00% | ↗ |
| 39 | 2016 | Daniel Goldberger Chief Executive Officer | 518.5K | — | — | — | — | — | 518.5K | 0.00% | ↗ |
| 40 | 2016 | Kevin O’Dare Area Vice President-East | 180.3K | — | — | 128.4K | — | 103.7K | 412.4K | 31.13% | ↗ |
| 41 | 2016 | Carl O’Connell President | 65.4K | 20.0K | — | 300.0K | — | — | 385.4K | 77.84% | ↗ |
| 42 | 2016 | John Gandolfo Chief Financial Officer (From July 6, 2010 to August 25,2017) | 360.0K | — | — | — | — | — | 360.0K | 0.00% | ↗ |
| 43 | 2016 | John Gandolfo Chief Financial Officer | 360.0K | — | — | — | — | — | 360.0K | 0.00% | ↗ |
| 44 | 2016 | John Gandolfo Former Chief Financial Officer | 360.0K | — | — | — | — | — | 360.0K | 0.00% | ↗ |
| 45 | 2016 | Carl O’Connell Chief Executive Officer | 65.4K | 20.0K | — | 274.1K | — | — | 359.4K | 76.24% | ↗ |
| 46 | 2016 | David Kirschman Executive Vice President and Chief Scientific Officer (From July 31,2015 to July 2, 2016) | 259.6K | — | — | — | — | — | 259.6K | 0.00% | ↗ |
| 47 | 2016 | Christopher Valois Vice President Sales and Marketing | 219.7K | 8.0K | — | — | — | — | 227.7K | 0.00% | ↗ |
| 48 | 2016 | Robert Di Silvio President (From July 1, 2014 to January 8, 2016) | — | — | — | — | — | 224.5K | 224.5K | 0.00% | ↗ |
| 49 | 2015 | Daniel Goldberger Chief Executive Officer | 404.0K | 285.0K | — | — | — | — | 689.0K | 0.00% | ↗ |
| 50 | 2015 | John Gandolfo Chief Financial Officer | 330.0K | 153.0K | — | — | — | — | 483.0K | 0.00% | ↗ |
| 51 | 2015 | David Kirschman Executive Vice President and Chief Scientific Officer (From July 31,2015 to July 2, 2016) | 209.6K | 62.5K | — | 76.9K | — | — | 349.0K | 22.03% | ↗ |
| 52 | 2015 | David Kirschman Executive Vice President and Chief Scientific Officer From July 31,2015 to present | 209.6K | 62.5K | — | 76.9K | — | — | 349.0K | 22.03% | ↗ |
| 53 | 2015 | Robert Di Silvio President (From July 1, 2014 to January 8, 2016) | 325.0K | — | — | — | — | — | 325.0K | 0.00% | ↗ |
| 54 | 2015 | Robert Di Silvio President | 325.0K | — | — | — | — | — | 325.0K | 0.00% | ↗ |
| 55 | 2014 | Daniel Goldberger Chief Executive Officer | 400.0K | 100.2K | — | — | — | — | 643.6K | 0.00% | ↗ |
| 56 | 2014 | Daniel Goldberger Chief Executive Officer | 400.0K | 100.2K | — | — | — | 143.4K | 643.6K | 0.00% | ↗ |
| 57 | 2014 | John Gandolfo Chief Financial Officer | 330.0K | 20.0K | — | 90.8K | — | — | 440.8K | 20.61% | ↗ |
| 58 | 2014 | John Gandolfo Chief Financial Officer | 330.0K | 20.0K | — | — | — | — | 440.8K | 0.00% | ↗ |
| 59 | 2014 | Robert Di Silvio President | 153.8K | — | — | 151.0K | — | 129.3K | 433.1K | 34.86% | ↗ |
| 60 | 2013 | Daniel Goldberger Chief Executive Officer | 143.1K | — | — | — | — | — | 1.24M | 0.00% | ↗ |
| 61 | 2013 | Daniel Goldberger Chief Executive Officer | 143.1K | — | — | — | — | — | 1.24M | 0.00% | ↗ |
| 62 | 2013 | John Gandolfo Chief Financial Officer | 321.5K | 100.8K | — | — | — | — | 525.3K | 0.00% | ↗ |
| 63 | 2013 | Darrel Holmes Chief Operating Officer | 254.6K | 84.0K | 68.3K | — | — | — | 441.7K | 15.47% | ↗ |
| 64 | 2013 | Nick Navarro VP of Sales | 240.0K | 70.5K | 22.8K | — | — | — | 368.0K | 6.19% | ↗ |
| 65 | 2013 | Gregory Juda Chief Scientific Officer | 200.0K | 71.1K | 22.8K | — | — | — | 328.7K | 6.93% | ↗ |
| 66 | 2013 | Guy S. Cook Chief Executive Officer | 156.1K | 47.0K | — | — | — | — | 203.0K | 0.00% | ↗ |
| 67 | 2012 | Guy S. Cook Chief Executive Officer | 500.0K | 100.0K | — | — | — | — | 738.2K | 0.00% | ↗ |
| 68 | 2012 | Nick Navarro VP of Sales | 233.1K | — | — | — | — | 13.3K | 507.4K | 0.00% | ↗ |
| 69 | 2012 | Nick Navarro National Sales Manager | 233.1K | — | — | — | — | — | 507.4K | 0.00% | ↗ |
| 70 | 2012 | John Gandolfo Chief Financial Officer | 299.9K | 50.0K | — | — | — | — | 446.7K | 0.00% | ↗ |
| 71 | 2012 | Gregory Juda Chief Scientific Officer | 179.8K | — | — | — | — | — | 290.3K | 0.00% | ↗ |
| 72 | 2012 | Darrel Holmes Chief Operating Officer | 199.2K | 50.0K | — | — | — | — | 249.2K | 0.00% | ↗ |
| 73 | 2011 | Guy S. Cook Chief Executive Officer | 500.0K | 50.0K | — | — | — | — | 550.0K | 0.00% | ↗ |
| 74 | 2011 | Robert Taggart EVP – National Sales | 240.0K | — | — | — | — | 298.6K | 538.6K | 0.00% | ↗ |
| 75 | 2011 | John Gandolfo Chief Financial Officer | 290.0K | 35.0K | — | — | — | — | 325.0K | 0.00% | ↗ |
| 76 | 2011 | Nick Navarro National Sales Manager | 177.7K | 50.0K | — | — | — | — | 287.5K | 0.00% | ↗ |
| 77 | 2011 | Darrel Holmes Chief Operating Officer | 162.7K | — | — | — | — | — | 162.7K | 0.00% | ↗ |
| 78 | 2010 | John Gandolfo Chief Financial Officer | 140.0K | — | — | 1.74M | — | — | 1.88M | 92.55% | ↗ |
| 79 | 2010 | John Gandolfo Chief Financial Officer | 140.0K | — | — | 1.74M | — | — | 1.88M | 92.55% | ↗ |
| 80 | 2010 | Robert Taggart EVP – National Sales | 249.2K | 3.8K | — | — | — | 176.4K | 429.4K | 0.00% | ↗ |
| 81 | 2010 | Jesus Hernandez VP - Biologics | 255.0K | 15.0K | — | — | — | — | 270.0K | 0.00% | ↗ |
| 82 | 2010 | Guy S. Cook Chairman of the Board and Chief Executive Officer | 240.0K | — | — | — | — | — | 240.0K | 0.00% | ↗ |
| 83 | 2010 | Guy S. Cook Chief Executive Officer | 240.0K | — | — | — | — | — | 240.0K | 0.00% | ↗ |
| 84 | 2010 | Darrel Holmes Chief Operating Officer | 100.0K | 30.0K | — | — | — | — | 130.0K | 0.00% | ↗ |
| 85 | 2010 | Jennifer Jarvis Former Director, Chief Executive Officer, President and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 86 | 2009 | Guy S. Cook Chairman of the Board and Chief Executive Officer | 230.8K | 40.0K | — | — | — | 34.9K | 305.6K | 0.00% | ↗ |
| 87 | 2009 | Jesus Hernandez VP - Biologics | 236.2K | — | — | — | — | 12.7K | 248.9K | 0.00% | ↗ |
| 88 | 2009 | Jennifer Jarvis Former Director, Chief Executive Officer, President and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 89 | 2008 | Guy S. Cook Chairman of the Board and Chief Executive Officer | 249.2K | — | — | — | — | 23.8K | 273.0K | 0.00% | ↗ |
| 90 | 2008 | Jesus Hernandez VP - Biologics | 197.3K | 27.5K | — | — | — | 67.0K | 236.8K | 0.00% | ↗ |
| 91 | 2008 | Jennifer Jarvis Former Director, Chief Executive Officer, President and Chief Financial Officer | 45.0K | — | — | — | — | — | 45.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sean E. Browne | President, Chief Executive Officer & Director | 762.9K | male |
| Mark Schallenberger | Chief Operations Officer | 674.8K | male |
| Scott C. Neils | Chief Financial Officer | 546.8K | male |
| Catherine Lundy | Vice President of Human Resources | — | female |
ESG Rating
ESG Score History MEDICAL - DEVICES
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for XTNT
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
